Inside Umbrella | Stocks
Stock Profile
Johnson & Johnson
Thanks to a strong pipeline, robust cash flows and a defensive business model, Johnson & Johnson remains a high-quality healthcare investment.
Aktuelle Unternehmensmeldungen
Johnson & Johnson
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
• 2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* • 2026 First-Quarter earnings per share…
Johnson & Johnson
Johnson & Johnson reports Q4 and Full-Year 2025 results
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024.
Johnson & Johnson